Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease

Blood (2010) 116 (21): 675.

https://doi.org/10.1182/blood.V116.21.675.675

Published: 2010

Journal Articles

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Shin Mineishi, MD, John Magenau, MD, Attaphol Pawarode, MD, Timothy Buck, Dawn Jones, RN, Koji Kato, MD, David Frame, Pharm.D, Lisa Kujawski, MD, Harry Paul Erba, MD, PhD, Yasser Khaled, MD, Edward M. Peres, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Carrie Kitko, MD, Sung Choi, MD, Gregory A. Yanik, MD, Thomas Braun, PhD, James L.M. Ferrara, MD, John E. Levine, MD

Blood (2008) 112 (11): 2150.

https://doi.org/10.1182/blood.V112.11.2150.2150

Published: 2008

Journal Articles

Elafin Is a Biomarker of Graft Versus Host Disease of the Skin

Sophie Paczesny, MD, PhD., John E. Levine, MD, Jason Hogan, PhD., Jeffrey Crawford, Thomas Braun, PhD, Hong Wang, PhD., Vitor Faca, PhD, Qing Zhang, Sharon Pitteri, PHD, Alice Chin, Sung Choi, MD, Carrie Kitko, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Shin Mineishi, MD, Joel Whitfield, Dawn Jones, RN, Samir Hanash, MD, PhD, James L.M. Ferrara, MD

Blood (2008) 112 (11): 716.

https://doi.org/10.1182/blood.V112.11.716.716

Published: 2008

Journal Articles

Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD.

John E. Levine, MD, MS, Sophie Paczesny, MD, Shin Mineishi, MD, Thomas Braun, PhD, Sung W. Choi, MD, Raymond J. Hutchinson, MD, MS, Dawn Jones, RN, Yasser Khaled, MD, Carrie Kitko, MD, Oleg Krijanovski, MD, Pavan Reddy, MD, Gregory Yanik, MD, James L.M. Ferrara, MD

Blood (2007) 110 (11): 39.

https://doi.org/10.1182/blood.V110.11.39.39

Published: 2007

Journal Articles

A Four Protein Plasma Fingerprint of Acute Graft Versus Host Disease (GVHD) Predicts Long Term Survival.

Sophie Paczesny, MD, Sung Choi, MD, Thomas Braun, PhD, Carrie Kitko, MD, Krijanovski Oleg, MD, Shawn G. Clouthier, Angela Weyand, Dan Bickley, Dawn Jones, RN, Joel Whitfield, John E. Levine, MD, James L. Ferrara, MD

Blood (2007) 110 (11): 38.

https://doi.org/10.1182/blood.V110.11.38.38

Published: 2007

Journal Articles

Changes in TNFR1 Levels in the First Week Post-Myeloablative HSCT Correlate with Severity and Incidence of GVHD and 1y TRM.

John E. Levine, MD, MS, Carrie Kitko, MD, Gregory Yanik, MD, Thomas Braun, PhD, Sophie Paczesny, MD, Shin Mineishi, MD, Oleg Krijanovski, MD, Dawn Jones, RN, Kenneth R. Cooke, MD, Joel Whitfield, Raymond J. Hutchinson, MD, MS, James L.M. Ferrara, MD

Blood (2006) 108 (11): 37.

https://doi.org/10.1182/blood.V108.11.37.37

Published: 2006

NARROW

Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Elafin Is a Biomarker of Graft Versus Host Disease of the Skin

Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD.

A Four Protein Plasma Fingerprint of Acute Graft Versus Host Disease (GVHD) Predicts Long Term Survival.

Changes in TNFR1 Levels in the First Week Post-Myeloablative HSCT Correlate with Severity and Incidence of GVHD and 1y TRM.

Email alerts

ASH Publications

American Society of Hematology

Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Elafin Is a Biomarker of Graft Versus Host Disease of the Skin

Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD.

A Four Protein Plasma Fingerprint of Acute Graft Versus Host Disease (GVHD) Predicts Long Term Survival.

Changes in TNFR1 Levels in the First Week Post-Myeloablative HSCT Correlate with Severity and Incidence of GVHD and 1y TRM.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only